A phase 3, randomised, observer-blinded, placebo controlled-trial evaluating the safety and immunogenicity of investigational SARS-CoV-2 mRNA vaccine CVnCoV in adult healthcare workers in Mainz (Germany)Regular paper Published on 2024-06-202024-09-05 Journal: Vaccine: X [Category] update2024, [키워드] COVID-19 CVnCoV Healthcare workers mRNA Phase 3 SARS-CoV-2 Vaccine [DOI] 10.1016/j.jvacx.2024.100512 PMC 바로가기 [Article Type] Regular paper
Humoral and cellular immune responses to CoronaVac up to one year after vaccinationArticle Published on 2022-10-212022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] all subject Antibody Response Antiviral CD4^{+} T cell cellular Cellular immune response cellular response clinical trial CoronaVac cytokine production cytokine profile defined effector memory evaluated follicular humoral Humoral response immune immune memory immune response impacted Inactivated vaccine individual induce memory Older peaked Phase 3 response SARS-CoV-2 SARS-CoV-2-specific IgG SARS-CoV-2-specific immune responses second dose sustained T cell activation T cell phenotype Tfh Th2 vaccination vaccine dose vaccinees [DOI] 10.3389/fimmu.2022.1032411 PMC 바로가기
Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trialArticle Published on 2022-10-132022-11-15 Journal: eLife [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Activation acute respiratory syndrome antibody approved blood sample Brazil CD4 cellular Chilean China circulating antibodies clinical clinical trial Concentration CoronaVac coronavirus coronavirus disease correlation COVID-19 difference dose Efficacy elicited Emergency use enrolled evaluate evaluated exhibited expression flow cytometry healthy Human humoral immune response humoral immune responses IFN-γ immune response immunization immunogenicity data immunology inactivated Indonesia Inflammation interferon marker Medicine Ministry of Health mononuclear cell multicenter neutralizing antibody neutralizing capacity pandemic PBMCs performed Peripheral blood Phase 3 phase 3 clinical trial phase 3 trial Production progression promote Randomized reported robust Sample SARS-CoV-2 SARS-CoV-2 vaccine secretion separated single center Stimulation T cell Trial Turkey Vaccine Vaccines variants of concern virus VOCs Volunteer were assessed [DOI] 10.7554/eLife.81477 PMC 바로가기
Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 VaccineArticle Published on 2022-09-212022-11-15 Journal: The Journal of Infectious Diseases [Category] SARS, 진단, 치료기술, [키워드] acute respiratory syndrome Ad26 Ad26.COV2.S Adenovirus Analysis antibody baseline Brazil coronavirus country COVID-19 Humoral immunity Immunity immunogenicity Impact participant Phase 3 postvaccination Preexisting immunity prevaccination recipient SARS-CoV-2 South Africa The United States Trial Vaccine vaccine-induced immune responses [DOI] 10.1093/infdis/jiac142 PMC 바로가기
Landscape of new drugs and targets in inflammatory bowel diseaseInflammatory Bowel Disease Published on 2022-09-162024-09-04 Journal: United European gastroenterology journal [Category] 대상포진, [키워드] clinical trials Inflammatory bowel disease New drugs Phase 1 Phase 2 Phase 3 [DOI] 10.1002/ueg2.12305 PMC 바로가기 [Article Type] Inflammatory Bowel Disease
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical TrialArticle Published on 2022-09-012022-11-15 Journal: Annals of internal medicine [Category] COVID19(2023년), SARS, 진단, [키워드] Analysis antibody blinded clinical COVID-19 Delta diagnosed Diagnosis double-blind Efficacy Elecsy evaluate evaluated had no higher odd immunoassay increase in Infection Infectious disease injection median Moderna mRNA-1273 occurred Odds ratio Older omicron participant PCR PCR-confirmed COVID-19 phase Phase 3 Placebo placebo recipient placebo-controlled polymerase chain Randomized risk Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 viral Seroconversion serum sample severe COVID-19 Swab tested The United States Treatment Trial vaccination Vaccination Status Vaccine vaccinee [DOI] 10.7326/M22-1300 PMC 바로가기
Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults비활성화된 전체 바이러스 면역증강제 COVID-19 백신 VLA2001의 안전성 및 면역원성: 건강한 성인을 대상으로 한 무작위, 용량 증량, 이중 맹검 1/2상 임상 시험Clinical Trial Published on 2022-09-012022-09-12 Journal: The Journal of Infection [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] Adjuvanted vaccine binding clinical development clinical trial conducted convalescent sera coronavirus COVID-19 COVID-19 vaccine CpG CpG 1018 dose Dose escalation dose-escalation double-blind evaluate expressing Frequency geometric mean titre GMT groups headache healthy High dose high-dose group highest dose IFN-γ IgG immunogenicity inactivated Inactivated vaccine injection Local medium N protein neutralizing antibody Open-label optimal dose outcome participant Phase 3 primary immunogenicity priming Randomized randomized trial RBD-binding IgG RBD-binding IgG antibody reactive recruited Registered reported S protein S protein binding IgG antibody Safety SARS-CoV-2 SARS-CoV-2 neutralizing antibody second vaccination severity significantly significantly higher statistically systemic reaction T-cell tested titre Tolerability vaccination Vaccine VLA2001 was selected Whole-virus vaccine. [DOI] 10.1016/j.jinf.2022.06.009 PMC 바로가기 [Article Type] Clinical Trial
Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial말라위에서 9개월에서 12세 사이의 어린이를 대상으로 한 장티푸스 접합 백신의 안전성 및 면역원성: 이중 맹검, 무작위 대조 시험의 중첩 하위 연구Clinical Trial Published on 2022-09-012022-09-12 Journal: The Lancet. Global health [Category] Fulltext, MERS, 살모넬라증, 임상, 진단, [키워드] 1:1 95% CI adverse event age analysed antibody assigned baseline children chronic health conditions clinical trial COVID-19 double-blind eight eligible eligible participant ELISA enrolled evaluated Evidence foundation geometric mean titre HIV IgG Immunosuppression intention-to-treat population intramuscularly Local Melinda Gate occurred outcomes participant Phase 3 provide public health randomised controlled trial Randomly reactogenicity receive recipient recipients Registered remained Safety screened titre Tolerability Trial typhoid fever vaccination Vaccine was collected [DOI] 10.1016/S2214-109X(22)00275-3 PMC 바로가기 [Article Type] Clinical Trial
Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial2019년 코로나바이러스 질환 입원 환자에서 사릴루맙의 효능 및 안전성: 무작위 임상 시험Randomized Controlled Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] 임상, 진단, [키워드] 95% CI 95% confidence interval adaptive adults hospitalized Analysis anti-IL-6R monoclonal antibody baseline benefit clinical clinical status coronavirus disease Coronavirus disease 2019 Corticosteroid Corticosteroids corticosteroids) COVID-19 Critical death double-blind Efficacy Efficacy and safety evaluated hazard ratio Hospitalized hospitalized patient hospitalized patients interleukin interleukin-6 interleukin-6 receptor intravenous mechanical ventilation Meta-analysis monoclonal antibodies Patient patients randomized Phase 2 phase 2/3 Phase 3 Placebo placebo-controlled trial Platform trial Post hoc analyses post-hoc analysis primary analysis population Primary outcome proportion Randomized receiving Relative risk risk risk difference Safety sarilumab therapy treated Treatment Trial with COVID-19 [DOI] 10.1093/cid/ciac153 PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in ChileArticle Published on 2022-08-242022-11-15 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, 치료기술, [키워드] activate acute respiratory syndrome Adverse reaction age analyzed binding domain blood sample cellular characterized Chilean circulating clinical trial CoronaVac coronavirus coronavirus 2 coronavirus disease COVID-19 dose effective vaccine enrolled healthy humoral IFN-γ IgG immunogenicity Immunoglobulin inactivated incidence induce injection interferon-γ Local measure Mild neutralizing antibody neutralizing capacity Pain peptide Phase 3 phase 3 clinical trial Placebo pool profiles promote Randomly RBD Registered reported respiratory Safe Safety SARS-CoV-2 SARS-CoV-2 antigens second dose secretion separated severe adverse event significant increase subset T cells T-cell Response the vaccine Vaccine Vaccines Volunteer volunteers was performed [DOI] 10.1093/cid/ciab823 PMC 바로가기